Pharmaceutical company Dr Reddy's Laboratories Ltd (BSE:500124) (NSE:DRREDDY) (NYSE:RDY) on Monday announced the availability of the US Food and Drug Administration (USFDA) approved Ciprofloxacin 0.3% and Dexamethasone 0.1% Otic Suspension, USP.

According to the company, the Ciprofloxacin 0.3% and Dexamethasone 0.1% Otic Suspension, USP is available as 7.5 ml fill in a 10 ml bottle.

The company added that Dexamethasone 0.1% Otic Suspension, USP is the therapeutic equivalent generic version of Ciprodex (ciprofloxacin 0.3% and dexamethasone 0.1%) Otic Suspension. The Ciprodex brand had US sales of approximately USD453m MAT for the most recent 12 months ending in June 2020 according to IQVIA Health.

In addition, the company said its ciprodex is indicated for the treatment of infections caused by susceptible isolates of Acute Otitis Media in paediatric patients with tympanostomy tubes due to Staphylococcus aureus, Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis and Pseudomonas aeruginosa, as well as Acute Otitis Externa in paediatric, adult and elderly patients due to Staphylococcu.